Skip to main content

Univercells Technologies

  • About Us
    • Our Team
    • Our History
  • scale-X™ bioreactor
  • NevoLine™ platform
    • NevoLine™ sIPV
    • NevoLine™ Upstream
  • Careers
    • Work Life
    • Open Positions
  • Library
  • Newsroom
  • Events
  • Contact

Press Releases

Home > Press Releases
Home > Press Releases

Press Releases

  • All categories
  • Press Releases
  • Product News
  • Corporate News
  • Customers Testimonial
  • Experts Opinion
Univercells Technologies and Exyte partnership prefabricated facilities for vaccines in the wake of covid19

New partnership with Exyte for rapid deployment of vaccine production plants in the wake of the COVID-19 pandemic

Exyte and Univercells Technologies are announcing a global partnership for optimized construction of modular standardized and flexible GMP manufacturing facilities for vaccines.

Read article "New partnership with Exyte for rapid deployment of vaccine production plants in the wake of the COVID-19 pandemic"
Posted on 14 May 202005 Oct 2020
Press Releases
Univercells secures €50M to accelerate the commercialization of its manufacturing technologies scale-X bioreactor and NevoLine platform

€50M investment from KKR platform to accelerate the commercialization of technologies portfolio

The investment will be deployed in a newly created subsidiary of Univercells focused on accelerating the industrialization and commercialization of Univercells’ manufacturing technologies

Read article "€50M investment from KKR platform to accelerate the commercialization of technologies portfolio"
Posted on 18 Feb 202005 Oct 2020
Press Releases
Univercells introduces the NevoLine platform

Introducing the NevoLine™ sIPV platform

Univercells and consortium partner Batavia Biosciences have been awarded a $4 million grant extension by the Bill & Melinda Gates Foundation to scale up their low-cost polio vaccine manufacturing technology.

Read article "Introducing the NevoLine™ sIPV platform"
Posted on 11 Jan 201905 Oct 2020
Press Releases

$12 million grant to develop breakthrough vaccine manufacturing platform

Univercells Receives $12 Million Grant to Develop Breakthrough Vaccine Manufacturing Platform

Read article "$12 million grant to develop breakthrough vaccine manufacturing platform"
Posted on 15 Dec 201605 Oct 2020
Press Releases

Discover

  • About Us
    • Our Team
    • Our History
  • scale-X™ bioreactor
  • NevoLine™ platform
    • NevoLine™ sIPV
    • NevoLine™ Upstream
  • Careers
    • Work Life
    • Open Positions
  • Library
  • Newsroom
  • Events
  • Contact

Contact

Chemin de la Vieille Cour 56a
1400 Nivelles – Belgium

+32 (0)2 318 83 48
Contact us 

LinkedIn

UNIVERCELLS TECHNOLOGIES 2020 — All Rights Reserved

  • Terms & Conditions
  • Privacy Policy
  • Cookie Policy
  • Website Terms of Use
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. However you may visit Cookie Settings to provide a controlled consent.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non Necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

Save & Accept
Powered by CookieYes